Cargando…

Comorbidities and Medication Use in Finnish Patients with Psoriasis: A Population-Based Registry Study

Therapeutic options for psoriasis vulgaris have changed during recent decades with the introduction of biologics. Few nationwide studies are available on psoriasis treatment patterns, and those from Finland predate the use of biologics. The aim of this retrospective, population-based registry study...

Descripción completa

Detalles Bibliográficos
Autores principales: VESIKANSA, Aino, MEHTÄLÄ, Juha, PESU, Marko, AALTONEN, Jaakko, KONTTINEN, Riikka, TASANEN, Kaisa, HUILAJA, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medical Journals Sweden, on behalf of the Society for Publication of Acta Dermato-Venereologica 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012470/
https://www.ncbi.nlm.nih.gov/pubmed/36892511
http://dx.doi.org/10.2340/actadv.v103.3491
_version_ 1784906611823738880
author VESIKANSA, Aino
MEHTÄLÄ, Juha
PESU, Marko
AALTONEN, Jaakko
KONTTINEN, Riikka
TASANEN, Kaisa
HUILAJA, Laura
author_facet VESIKANSA, Aino
MEHTÄLÄ, Juha
PESU, Marko
AALTONEN, Jaakko
KONTTINEN, Riikka
TASANEN, Kaisa
HUILAJA, Laura
author_sort VESIKANSA, Aino
collection PubMed
description Therapeutic options for psoriasis vulgaris have changed during recent decades with the introduction of biologics. Few nationwide studies are available on psoriasis treatment patterns, and those from Finland predate the use of biologics. The aim of this retrospective, population-based registry study was to identify patients with psoriasis vulgaris and their treatment patterns in the secondary care setting in Finland. The study cohort included 41,456 adults with a diagnosis of psoriasis vulgaris in the public secondary healthcare setting from 2012 through 2018. Data on comorbidities, pharmacotherapy, and phototherapy were collected from nationwide healthcare and drug registries. Patients in the cohort had a wide range of comorbidities, with 14.9% having psoriatic arthritis. Treatment was based largely on topical and conventional systemic medications. Conventional medications were used by 28.9% of patients, and methotrexate was the most common option (20.9%). Biologics were used by 7.3% of patients, mostly as second- and third-line treatment. The use of conventional systemic medications, topical treatments, and phototherapy decreased after the initiation of biologics. This study of psoriasis vulgaris in Finland provides a framework for the development of future care practices. SIGNIFICANCE This population-based study identified adult patients with psoriasis vulgaris (psoriasis) and their treatment patterns in the secondary care setting in Finland. The results indicate that patients with psoriasis had a wide range of comorbidities, with 15% having psoriatic arthritis. Treatment was based largely on topical treatments. Conventional systemic (oral) medications were used by approximately 30% and biological treatments by 7% of patients. The results provide important information on psoriasis patients and their current treatment patterns and form a framework for the development of future care practices for psoriasis in Finland.
format Online
Article
Text
id pubmed-10012470
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Medical Journals Sweden, on behalf of the Society for Publication of Acta Dermato-Venereologica
record_format MEDLINE/PubMed
spelling pubmed-100124702023-03-15 Comorbidities and Medication Use in Finnish Patients with Psoriasis: A Population-Based Registry Study VESIKANSA, Aino MEHTÄLÄ, Juha PESU, Marko AALTONEN, Jaakko KONTTINEN, Riikka TASANEN, Kaisa HUILAJA, Laura Acta Derm Venereol Original Report Therapeutic options for psoriasis vulgaris have changed during recent decades with the introduction of biologics. Few nationwide studies are available on psoriasis treatment patterns, and those from Finland predate the use of biologics. The aim of this retrospective, population-based registry study was to identify patients with psoriasis vulgaris and their treatment patterns in the secondary care setting in Finland. The study cohort included 41,456 adults with a diagnosis of psoriasis vulgaris in the public secondary healthcare setting from 2012 through 2018. Data on comorbidities, pharmacotherapy, and phototherapy were collected from nationwide healthcare and drug registries. Patients in the cohort had a wide range of comorbidities, with 14.9% having psoriatic arthritis. Treatment was based largely on topical and conventional systemic medications. Conventional medications were used by 28.9% of patients, and methotrexate was the most common option (20.9%). Biologics were used by 7.3% of patients, mostly as second- and third-line treatment. The use of conventional systemic medications, topical treatments, and phototherapy decreased after the initiation of biologics. This study of psoriasis vulgaris in Finland provides a framework for the development of future care practices. SIGNIFICANCE This population-based study identified adult patients with psoriasis vulgaris (psoriasis) and their treatment patterns in the secondary care setting in Finland. The results indicate that patients with psoriasis had a wide range of comorbidities, with 15% having psoriatic arthritis. Treatment was based largely on topical treatments. Conventional systemic (oral) medications were used by approximately 30% and biological treatments by 7% of patients. The results provide important information on psoriasis patients and their current treatment patterns and form a framework for the development of future care practices for psoriasis in Finland. Medical Journals Sweden, on behalf of the Society for Publication of Acta Dermato-Venereologica 2023-03-09 /pmc/articles/PMC10012470/ /pubmed/36892511 http://dx.doi.org/10.2340/actadv.v103.3491 Text en © Published by Medical Journals Sweden, on behalf of the Foundation for Rehabilitation Information https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Original Report
VESIKANSA, Aino
MEHTÄLÄ, Juha
PESU, Marko
AALTONEN, Jaakko
KONTTINEN, Riikka
TASANEN, Kaisa
HUILAJA, Laura
Comorbidities and Medication Use in Finnish Patients with Psoriasis: A Population-Based Registry Study
title Comorbidities and Medication Use in Finnish Patients with Psoriasis: A Population-Based Registry Study
title_full Comorbidities and Medication Use in Finnish Patients with Psoriasis: A Population-Based Registry Study
title_fullStr Comorbidities and Medication Use in Finnish Patients with Psoriasis: A Population-Based Registry Study
title_full_unstemmed Comorbidities and Medication Use in Finnish Patients with Psoriasis: A Population-Based Registry Study
title_short Comorbidities and Medication Use in Finnish Patients with Psoriasis: A Population-Based Registry Study
title_sort comorbidities and medication use in finnish patients with psoriasis: a population-based registry study
topic Original Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012470/
https://www.ncbi.nlm.nih.gov/pubmed/36892511
http://dx.doi.org/10.2340/actadv.v103.3491
work_keys_str_mv AT vesikansaaino comorbiditiesandmedicationuseinfinnishpatientswithpsoriasisapopulationbasedregistrystudy
AT mehtalajuha comorbiditiesandmedicationuseinfinnishpatientswithpsoriasisapopulationbasedregistrystudy
AT pesumarko comorbiditiesandmedicationuseinfinnishpatientswithpsoriasisapopulationbasedregistrystudy
AT aaltonenjaakko comorbiditiesandmedicationuseinfinnishpatientswithpsoriasisapopulationbasedregistrystudy
AT konttinenriikka comorbiditiesandmedicationuseinfinnishpatientswithpsoriasisapopulationbasedregistrystudy
AT tasanenkaisa comorbiditiesandmedicationuseinfinnishpatientswithpsoriasisapopulationbasedregistrystudy
AT huilajalaura comorbiditiesandmedicationuseinfinnishpatientswithpsoriasisapopulationbasedregistrystudy